My watch list  


Systematic (IUPAC) name
acetyl-D-β-naphthylalanyl- D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L- N-methyl- tyrosyl-D-asparagyl-L-leucyl-L-N(e )-isopropyl-lysyl-L-prolyl-D-alanyl-amide
CAS number 183552-38-7
ATC code L02BX01
PubChem  ?
DrugBank BTD00051
Chemical data
Formula C72H95ClN14O14 
Mol. mass 1416.06 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 96–99%
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes  ?

Abarelix is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called Gonadotropin-releasing hormone antagonists.

It is marketed by Speciality European Pharma as Plenaxis. Plenaxis has received marketing authorisation in Germany.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Abarelix". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE